PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer
Dr. Davis brings more than 20 years of industry experience to lead the advancement of the company’s clinical stage pipeline of T-SIGn® immuno-oncology therapeutics for the treatment of solid tumors New CEO will establish U.S. operations in the Boston area to accelerate the company’s mission to positively impact the lives of people living with cancer … [Read more…]
